BR100 Decreased By (-0.73%)
BR30 Decreased By (-1.04%)
KSE100 Decreased By (-0.3%)
KSE30 Decreased By (-0.41%)
BECO 5.56 Increased By ▲ 0.03 (0.54%)
BML 57.40 Decreased By ▼ -0.55 (-0.95%)
BOP 35.09 Decreased By ▼ -0.11 (-0.31%)
CNERGY 8.27 Increased By ▲ 0.05 (0.61%)
DCL 11.72 Increased By ▲ 0.08 (0.69%)
FCCL 56.11 Decreased By ▼ -0.79 (-1.39%)
FCSC 5.40 Increased By ▲ 0.01 (0.19%)
FFL 18.08 Decreased By ▼ -0.05 (-0.28%)
FNEL 1.31 No Change ▼ 0.00 (0%)
HUMNL 11.24 Increased By ▲ 0.06 (0.54%)
KEL 8.17 Increased By ▲ 0.02 (0.25%)
KOSM 6.89 Decreased By ▼ -0.07 (-1.01%)
MLCF 100.80 Increased By ▲ 0.28 (0.28%)
NBP 203.37 Decreased By ▼ -0.14 (-0.07%)
PACE 11.36 Increased By ▲ 0.15 (1.34%)
PAEL 42.92 Increased By ▲ 0.17 (0.4%)
PIAHCLA 27.32 Increased By ▲ 1.01 (3.84%)
PIBTL 18.10 Increased By ▲ 0.16 (0.89%)
PPL 243.26 Increased By ▲ 1.32 (0.55%)
PRL 35.80 Decreased By ▼ -0.17 (-0.47%)
PTC 65.30 Decreased By ▼ -0.28 (-0.43%)
SEARL 94.69 Increased By ▲ 0.29 (0.31%)
SSGC 32.19 Increased By ▲ 0.87 (2.78%)
TELE 9.22 Increased By ▲ 0.15 (1.65%)
THCCL 67.21 Decreased By ▼ -0.41 (-0.61%)
TPLP 10.75 Increased By ▲ 0.51 (4.98%)
TREET 26.11 Increased By ▲ 0.27 (1.04%)
TRG 65.40 Decreased By ▼ -1.28 (-1.92%)
WAVES 11.17 Increased By ▲ 0.12 (1.09%)
WTL 1.28 Decreased By ▼ -0.01 (-0.78%)
Markets

Bayer to cut more than 1.5bn euros in costs

  • The cash flow freed up would be allocated for investments in further innovation, profitable growth opportunities and debt reduction.
  • Bayer said it expects 2021 sales to be about the same as in 2020, despite significant headwinds from COVID-19.
Published September 30, 2020 Updated September 30, 2020 11:28pm
By

BERLIN: German drugs company Bayer AG announced plans on Wednesday for more than 1.5 billion euros ($1.76 billion)of cost cuts as of 2024, on top of savings announced in 2018, as it battles with a slowdown in the agricultural market.

The cash flow freed up would be allocated for investments in further innovation, profitable growth opportunities and debt reduction. It said the restructuring, which may also lead to extra job cuts, is in the early stages of planning.

Bayer said it expects 2021 sales to be about the same as in 2020, despite significant headwinds from COVID-19, especially in the agricultural market, and said it expects core earnings per share to be slightly lower at constant exchange rates.

Comments

Comments are closed for this article.